{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:41:58Z","timestamp":1777448518039,"version":"3.51.4"},"reference-count":93,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jfma.2021.03.032","type":"journal-article","created":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T05:16:18Z","timestamp":1619241378000},"page":"1811-1820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Taiwan mini-frontier of primary aldosteronism: Updating treatment and comorbidities detection"],"prefix":"10.1016","volume":"120","author":[{"given":"Chieh-Kai","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Yao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Chun","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7728-6674","authenticated-orcid":false,"given":"Zheng-Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9616-0874","authenticated-orcid":false,"given":"Chun-Yi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Chieh","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I-Weng","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuo-Hsin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vin-Cent","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vin-Cent","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chieh-Kai","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jui-Hsiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Che-Hsiung","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leay Kiaw","family":"Er","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Hui","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Chou","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Chin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lian-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu-Chang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin-Chen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kao-Lang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo-Meng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuo-How","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Chieh","family":"Jeff Chueh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Cheng","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Chu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruoh-Fang","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwan-Dun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2021.03.032_bib1","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1210\/jc.2003-031337","article-title":"Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents","volume":"89","author":"Mulatero","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jfma.2021.03.032_bib2","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(08)60834-X","article-title":"Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study","volume":"371","author":"Douma","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2021.03.032_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1055\/s-0031-1295438","article-title":"Prevalence of primary aldosteronism in patient's cohorts and in population-based studies\u2013a review of the current literature","volume":"44","author":"Hannemann","year":"2012","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.jfma.2021.03.032_bib4","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1161\/01.CIR.95.6.1471","article-title":"Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma","volume":"95","author":"Rossi","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2021.03.032_bib5","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1097\/HJH.0b013e3283495cbb","article-title":"Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment","volume":"29","author":"Wu","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.jfma.2021.03.032_bib6","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1210\/jc.2013-2805","article-title":"Long-term cardio- and cerebrovascular events in patients with primary aldosteronism","volume":"98","author":"Mulatero","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jfma.2021.03.032_bib7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/HYPERTENSIONAHA.113.01060","article-title":"Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study","volume":"62","author":"Savard","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.jfma.2021.03.032_bib8","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1210\/jc.2005-1733","article-title":"Prevalence and characteristics of the metabolic syndrome in primary aldosteronism","volume":"91","author":"Fallo","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jfma.2021.03.032_bib9","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1097\/HJH.0000000000001361","article-title":"Risk of new-onset diabetes mellitus in primary aldosteronism: a population study over 5 years","volume":"35","author":"Wu","year":"2017","journal-title":"J Hypertens"},{"key":"10.1016\/j.jfma.2021.03.032_bib10","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/jbmr.3033","article-title":"Risk of fracture in primary aldosteronism: a population-based cohort study","volume":"32","author":"Wu","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jfma.2021.03.032_bib11","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jfma.2017.06.004","article-title":"Case detection and diagnosis of primary aldosteronism - the consensus of Taiwan Society of Aldosteronism","volume":"116","author":"Wu","year":"2017","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2021.03.032_bib12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jfma.2018.01.006","article-title":"Targeted treatment of primary aldosteronism - the consensus of Taiwan Society of Aldosteronism","volume":"118","author":"Huang","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2021.03.032_bib13","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.jacc.2015.09.001","article-title":"Further evolution of the ACC\/AHA clinical practice guideline recommendation classification system: a report of the American college of cardiology\/American heart association Task Force on clinical practice Guidelines","volume":"67","author":"Halperin","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2021.03.032_bib14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jfma.2021.03.032_bib15","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jfma.2021.03.032_bib16","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1097\/HJH.0000000000002070","article-title":"Clinical and biochemical outcomes after adrenalectomy and medical treatment in patients with unilateral primary aldosteronism","volume":"37","author":"Katabami","year":"2019","journal-title":"J Hypertens"},{"key":"10.1016\/j.jfma.2021.03.032_bib17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jfma.2018.01.006","article-title":"Targeted treatment of primary aldosteronism - the consensus of Taiwan Society of Aldosteronism","volume":"118","author":"Huang","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2021.03.032_bib18","doi-asserted-by":"crossref","first-page":"32103","DOI":"10.1038\/srep32103","article-title":"Long term outcome of Aldosteronism after target treatments","volume":"6","author":"Wu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2021.03.032_bib19","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","article-title":"Renal outcomes in medically and surgically treated primary aldosteronism","volume":"72","author":"Hundemer","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.jfma.2021.03.032_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/HJH.0b013e3283599b6a","article-title":"Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension","volume":"31","author":"Colussi","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.jfma.2021.03.032_bib21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone","volume":"200","author":"Lainscak","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jfma.2021.03.032_bib22","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J Endocrinol"},{"key":"10.1016\/j.jfma.2021.03.032_bib23","doi-asserted-by":"crossref","first-page":"R19","DOI":"10.1530\/EJE-17-0990","article-title":"Management of endocrine disease: diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited","volume":"179","author":"Williams","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jfma.2021.03.032_bib24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1517\/14656566.9.4.509","article-title":"Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism","volume":"9","author":"Karagiannis","year":"2008","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.jfma.2021.03.032_bib25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/hr.2015.129","article-title":"Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism","volume":"39","author":"Karashima","year":"2016","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jfma.2021.03.032_bib26","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","article-title":"A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism","volume":"29","author":"Parthasarathy","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.jfma.2021.03.032_bib27","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","article-title":"Three new epoxy-spirolactone derivatives: characterization in\u00a0vivo and in\u00a0vitro","volume":"240","author":"de Gasparo","year":"1987","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.jfma.2021.03.032_bib28","first-page":"540","article-title":"Disturbances in sexual differentiation of rat foetuses following spironolactone treatment","volume":"95","author":"Hecker","year":"1980","journal-title":"Acta Endocrinol (Copenh)"},{"key":"10.1016\/j.jfma.2021.03.032_bib29","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/HYPERTENSIONAHA.111.187237","article-title":"Eplerenone use in primary aldosteronism during pregnancy","volume":"59","author":"Cabassi","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.jfma.2021.03.032_bib30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ccr3.355","article-title":"Eplerenone use in primary aldosteronism during pregnancy","volume":"4","author":"Gunganah","year":"2016","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.jfma.2021.03.032_bib31","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ando.2016.04.009","article-title":"Primary aldosteronism and pregnancy","volume":"77","author":"Landau","year":"2016","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.jfma.2021.03.032_bib32","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1530\/EJE-14-0444","article-title":"Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy","volume":"172","author":"Riester","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jfma.2021.03.032_bib33","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1001\/jamacardio.2018.2003","article-title":"Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism","volume":"3","author":"Hundemer","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jfma.2021.03.032_bib34","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/cvr\/26.7.671","article-title":"Reactive and reparative myocardial fibrosis in arterial hypertension in the rat","volume":"26","author":"Brilla","year":"1992","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jfma.2021.03.032_bib35","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1161\/01.HYP.27.5.1039","article-title":"Changes in left ventricular anatomy and function in hypertension and primary aldosteronism","volume":"27","author":"Rossi","year":"1996","journal-title":"Hypertension"},{"key":"10.1016\/j.jfma.2021.03.032_bib36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjhyper.2005.05.013","article-title":"Role of aldosterone in left ventricular hypertrophy in hypertension","volume":"19","author":"Matsumura","year":"2006","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jfma.2021.03.032_bib37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1291\/hypres.20.85","article-title":"Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension","volume":"20","author":"Tanabe","year":"1997","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jfma.2021.03.032_bib38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1161\/01.HYP.0000023182.68420.EB","article-title":"Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism","volume":"40","author":"Rossi","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.jfma.2021.03.032_bib39","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.HYP.0000052542.68896.2B","article-title":"Myocardial ultrasonic backscatter in hypertension: relation to aldosterone and endothelin","volume":"41","author":"Kozakova","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.jfma.2021.03.032_bib40","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","article-title":"Cardiovascular outcomes in patients with primary aldosteronism after treatment","volume":"168","author":"Catena","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jfma.2021.03.032_bib41","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/clc.20270","article-title":"Myocardial and aortic stiffening in the early course of primary aldosteronism","volume":"31","author":"Tsioufis","year":"2008","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jfma.2021.03.032_bib42","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.004815","article-title":"Cardiac remodeling in patients with primary and secondary aldosteronism: a tissue Doppler study","volume":"9","author":"Cesari","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jfma.2021.03.032_bib43","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HJH.0000000000000619","article-title":"Circulating tissue inhibitor of matrix metalloproteinase-1 is associated with aldosterone-induced diastolic dysfunction","volume":"33","author":"Hung","year":"2015","journal-title":"J Hypertens"},{"key":"10.1016\/j.jfma.2021.03.032_bib44","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/HYPERTENSIONAHA.107.095448","article-title":"Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism","volume":"50","author":"Catena","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.jfma.2021.03.032_bib45","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.surg.2011.02.006","article-title":"Reversal of myocardial fibrosis in patients with unilateral hyperaldosteronism receiving adrenalectomy","volume":"150","author":"Lin","year":"2011","journal-title":"Surgery"},{"key":"10.1016\/j.jfma.2021.03.032_bib46","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1470320310376424","article-title":"Factors influencing left ventricular mass regression in patients with primary aldosteronism post adrenalectomy","volume":"12","author":"Lin","year":"2011","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.jfma.2021.03.032_bib47","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/jbmr.3033","article-title":"Risk of fracture in primary aldosteronism: a population-based cohort study","volume":"32","author":"Wu","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jfma.2021.03.032_bib48","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1210\/jc.2016-3206","article-title":"Primary aldosteronism as a risk factor for vertebral fracture","volume":"102","author":"Notsu","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jfma.2021.03.032_bib49","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1007\/s00198-013-2399-1","article-title":"Bone health and aldosterone excess","volume":"24","author":"Ceccoli","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jfma.2021.03.032_bib50","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1002\/jbmr.1660","article-title":"Bone involvement in aldosteronism","volume":"27","author":"Salcuni","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jfma.2021.03.032_bib51","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1530\/EJE-17-0417","article-title":"Primary aldosteronism as a cause of secondary osteoporosis","volume":"177","author":"Salcuni","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jfma.2021.03.032_bib52","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0002-9343(85)90328-6","article-title":"Calcium metabolism and parathyroid function in primary aldosteronism","volume":"78","author":"Resnick","year":"1985","journal-title":"Am J Med"},{"key":"10.1016\/j.jfma.2021.03.032_bib53","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/0895-7061(95)00182-O","article-title":"Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas","volume":"8","author":"Rossi","year":"1995","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jfma.2021.03.032_bib54","doi-asserted-by":"crossref","first-page":"E75","DOI":"10.1210\/jc.2011-2183","article-title":"Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study","volume":"97","author":"Pilz","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jfma.2021.03.032_bib55","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/HJH.0b013e32834f0451","article-title":"Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism","volume":"30","author":"Maniero","year":"2012","journal-title":"J Hypertens"},{"key":"10.1016\/j.jfma.2021.03.032_bib56","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/HYPERTENSIONAHA.112.195891","article-title":"Hyperparathyroidism can be useful in the identification of primary aldosteronism due to aldosterone-producing adenoma","volume":"60","author":"Rossi","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.jfma.2021.03.032_bib57","doi-asserted-by":"crossref","first-page":"E638","DOI":"10.1210\/jc.2012-4007","article-title":"Serum parathyroid hormone in relation to all-cause and cardiovascular mortality: the Hoorn study","volume":"98","author":"van Ballegooijen","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jfma.2021.03.032_bib58","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/eurheartj\/ehq109","article-title":"Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography","volume":"31","author":"Pilz","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jfma.2021.03.032_bib59","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/jhh.2013.32","article-title":"Clinical characteristics of patients with resistant hypertension: the RESIST-POL study","volume":"27","author":"Florczak","year":"2013","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.jfma.2021.03.032_bib60","doi-asserted-by":"crossref","first-page":"363","DOI":"10.5603\/EP.2013.0019","article-title":"Relationship between primary aldosteronism and obstructive sleep apnoea, metabolic abnormalities and cardiac structure in patients with resistant hypertension","volume":"64","author":"Prejbisz","year":"2013","journal-title":"Endokrynol Pol"},{"key":"10.1016\/j.jfma.2021.03.032_bib61","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1097\/HJH.0b013e3283492219","article-title":"Positive relationship of sleep apnea to hyperaldosteronism in an ethnically diverse population","volume":"29","author":"Sim","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.jfma.2021.03.032_bib62","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/jhh.2011.47","article-title":"Resistant hypertension, obstructive sleep apnoea and aldosterone","volume":"26","author":"Dudenbostel","year":"2012","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.jfma.2021.03.032_bib63","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1055\/s-0043-122887","article-title":"Primary aldosteronism and obstructive sleep apnea: is this A bidirectional relationship?","volume":"49","author":"Prejbisz","year":"2017","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.jfma.2021.03.032_bib64","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/jhh.2017.28","article-title":"Treatment of primary aldosteronism is associated with a reduction in the severity of obstructive sleep apnoea","volume":"31","author":"Wolley","year":"2017","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.jfma.2021.03.032_bib65","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1681\/ASN.2004100878","article-title":"Relative glomerular hyperfiltration in primary aldosteronism","volume":"16","author":"Ribstein","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.03.032_bib66","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","article-title":"Renal damage in primary aldosteronism: results of the PAPY Study","volume":"48","author":"Rossi","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.jfma.2021.03.032_bib67","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","article-title":"Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1","volume":"49","author":"Shibata","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.jfma.2021.03.032_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1523-1755.2004.00701.x","article-title":"Aldosterone in the development and progression of renal injury","volume":"66","author":"Hollenberg","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.jfma.2021.03.032_bib69","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1001\/jama.295.22.2638","article-title":"Long-term renal outcomes in patients with primary aldosteronism","volume":"295","author":"Sechi","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2021.03.032_bib70","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1210\/jc.2013-2180","article-title":"Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases","volume":"99","author":"Iwakura","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jfma.2021.03.032_bib71","article-title":"Risk factors for renal impairment revealed after unilateral adrenalectomy in patients with primary aldosteronism","volume":"95","author":"Kim","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jfma.2021.03.032_bib72","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/jclinpath-2012-201287","article-title":"Immunohistochemistry improves histopathologic diagnosis in primary aldosteronism","volume":"66","author":"Volpe","year":"2013","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jfma.2021.03.032_bib73","doi-asserted-by":"crossref","first-page":"E4591","DOI":"10.1073\/pnas.1505529112","article-title":"Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands","volume":"112","author":"Nishimoto","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jfma.2021.03.032_bib74","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.mce.2013.11.022","article-title":"Development of monoclonal antibodies against human CYP11B1 and CYP11B2","volume":"383","author":"Gomez-Sanchez","year":"2014","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jfma.2021.03.032_bib75","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1210\/jc.2009-2010","article-title":"Adrenocortical zonation in humans under normal and pathological conditions","volume":"95","author":"Nishimoto","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jfma.2021.03.032_bib76","doi-asserted-by":"crossref","first-page":"E1341","DOI":"10.1210\/jc.2013-4255","article-title":"Adrenal nodularity and somatic mutations in primary aldosteronism: one node is the culprit?","volume":"99","author":"Dekkers","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jfma.2021.03.032_bib77","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1210\/jc.2012-3726","article-title":"Histopathological diagnosis of primary aldosteronism using CYP11B2 immunohistochemistry","volume":"98","author":"Nanba","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jfma.2021.03.032_bib78","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1210\/jc.2015-3285","article-title":"Case report: nodule development from subcapsular aldosterone-producing cell clusters causes hyperaldosteronism","volume":"101","author":"Nishimoto","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jfma.2021.03.032_bib79","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1161\/HYPERTENSIONAHA.118.12070","article-title":"Genetic characteristics of aldosterone-producing adenomas in blacks","volume":"73","author":"Nanba","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.jfma.2021.03.032_bib80","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1161\/HYPERTENSIONAHA.119.14177","article-title":"Genetic, cellular, and molecular heterogeneity in adrenals with aldosterone-producing adenoma","volume":"75","author":"De Sousa","year":"2020","journal-title":"Hypertension (Dallas, Tex. : 1979)"},{"key":"10.1016\/j.jfma.2021.03.032_bib81","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1161\/HYPERTENSIONAHA.118.11465","article-title":"Immunohistopathology and steroid profiles associated with biochemical outcomes after adrenalectomy for unilateral primary aldosteronism","volume":"72","author":"Meyer","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.jfma.2021.03.032_bib82","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1126\/science.1198785","article-title":"K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension","volume":"331","author":"Choi","year":"2011","journal-title":"Science"},{"issue":"440\u20134","key":"10.1016\/j.jfma.2021.03.032_bib83","first-page":"4e1","article-title":"Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension","volume":"45","author":"Beuschlein","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jfma.2021.03.032_bib84","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/ng.2695","article-title":"Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism","volume":"45","author":"Scholl","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jfma.2021.03.032_bib85","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.06315","article-title":"Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism","volume":"4","author":"Scholl","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.jfma.2021.03.032_bib86","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/hmg\/ddt484","article-title":"WNT\/beta-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production","volume":"23","author":"Berthon","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jfma.2021.03.032_bib87","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1097\/HJH.0000000000000186","article-title":"KCNJ5 gene somatic mutations affect cardiac remodelling but do not preclude cure of high blood pressure and regression of left ventricular hypertrophy in primary aldosteronism","volume":"32","author":"Rossi","year":"2014","journal-title":"J Hypertens"},{"key":"10.1016\/j.jfma.2021.03.032_bib88","doi-asserted-by":"crossref","first-page":"191","DOI":"10.5551\/jat.24455","article-title":"Comparison of cardiovascular complications in patients with and without KCNJ5 gene mutations harboring aldosterone-producing adenomas","volume":"22","author":"Kitamoto","year":"2015","journal-title":"J Atherosclerosis Thromb"},{"key":"10.1016\/j.jfma.2021.03.032_bib89","doi-asserted-by":"crossref","first-page":"11396","DOI":"10.1038\/srep11396","article-title":"Prevalence and clinical correlates of somatic mutation in aldosterone producing adenoma-Taiwanese population","volume":"5","author":"Wu","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2021.03.032_bib90","doi-asserted-by":"crossref","first-page":"39121","DOI":"10.1038\/srep39121","article-title":"The prevalence of CTNNB1 mutations in primary aldosteronism and consequences for clinical outcomes","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2021.03.032_bib91","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1210\/jc.2015-3239","article-title":"Molecular heterogeneity in aldosterone-producing adenomas","volume":"101","author":"Nanba","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jfma.2021.03.032_bib92","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1210\/jc.2018-01004","article-title":"Targeted molecular characterization of aldosterone-producing adenomas in white Americans","volume":"103","author":"Nanba","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jfma.2021.03.032_bib93","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1161\/HYPERTENSIONAHA.118.12070","article-title":"Genetic characteristics of aldosterone-producing adenomas in blacks","volume":"73","author":"Nanba","year":"2019","journal-title":"Hypertension (Dallas, Tex. : 1979)"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664621001376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664621001376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:45:34Z","timestamp":1760539534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664621001376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":93,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0929664621001376"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2021.03.032","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Taiwan mini-frontier of primary aldosteronism: Updating treatment and comorbidities detection","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2021.03.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}